Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06898515 · ClinicalTrials.gov registry record · Phase 3

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

A Phase 3 study of Acute Decompensated Heart Failure, sponsored by Reprieve Cardiovascular.

Recruiting
Registry status
Phase 3
Development phase
400
Enrollment target
20
Study locations

NCT06898515 is a Phase 3 study of Acute Decompensated Heart Failure that is actively recruiting participants, run by Reprieve Cardiovascular. The registered enrollment target is 400 participants, roughly in line with the 426-participant average among 12 other Acute Decompensated Heart Failure trials with a reported enrollment target. The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06898515, a Phase 3 study of Acute Decompensated Heart Failure, is actively recruiting participants, sponsored by Reprieve Cardiovascular.

RECRUITING
Registry status
Phase 3
Development phase
400 participants
Enrollment target
20
Study locations

Study Summary

The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more efficiently decongest ADHF patients in comparison to Control Therapy.

Conditions Studied

Acute Decompensated Heart Failure

Interventions

  • DEVICE Reprieve System
  • DRUG furosemide infusion

Study Locations (20)

California

  • University of California Irvine - Irvine
  • Scripps Memorial Hospital - La Jolla
  • UC Davis Medical Center - Sacramento

Georgia

  • Piedmont Atlanta Hospital - Atlanta
  • Piedmont Augusta Hospital - Augusta
  • Northeast Georgia Medical Center - Gainesville

Michigan

  • Trinity Health Ann Arbor Hospital - Ann Arbor
  • Corewell Health Butterworth Hospital - Grand Rapids
  • Corewell William Beaumont University Hospital - Royal Oak

Missouri

  • Harry S. Truman Veteran's Memorial Hospital - Columbia
  • St. Louis VA - St Louis
  • Washington University - St Louis

Florida

  • University of Florida - Gainesville

Illinois

  • Advocate Christ Medical Center - Oak Lawn

Kansas

  • University of Kansas Medical Center - Kansas City

Kentucky

  • University of Louisville Hospital - Louisville

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2025-07-14
Est. Completion 2027-12
Phase Phase 3

Sponsor

Reprieve Cardiovascular

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06898515

The ClinicalTrials.gov registry entry for NCT06898515 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 426-participant average among 12 other Acute Decompensated Heart Failure trials with a reported enrollment target. The listed sponsor is Reprieve Cardiovascular, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Decompensated Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Reprieve System is the first listed.

NCT06898515 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Georgia, Michigan.

Frequently Asked Questions

What is clinical trial NCT06898515 about?

NCT06898515 is a clinical study titled "Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)". The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more ...

What is the current status of trial NCT06898515?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2025-07-14. Estimated completion is 2027-12.

What conditions does trial NCT06898515 study?

This clinical trial studies the following conditions: Acute Decompensated Heart Failure.

What interventions are being tested in trial NCT06898515?

The interventions under investigation include: Reprieve System (DEVICE), furosemide infusion (DRUG).

Who is sponsoring clinical trial NCT06898515?

This trial is sponsored by Reprieve Cardiovascular, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06898515 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Decompensated Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Decompensated Heart Failure

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.